Rathnasinghe, Raveen
Salvatore, Mirella
Zheng, Hongyong
Jangra, Sonia
Kehrer, Thomas
Mena, Ignacio
Schotsaert, Michael
Muster, Thomas
Palese, Peter
García-Sastre, Adolfo
Funding for this research was provided by:
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (75N93019C00051, 75N93019C00051)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI141226, R01AI141226)
Article History
Received: 28 June 2021
Accepted: 19 October 2021
First Online: 12 November 2021
Competing interests
: AG–S and PP are inventors in patents owned by the Icahn School of Medicine and licensed to Vivaldi Biosciences concerning the use of NS1 deficient viruses as human vaccines and to BI Vetmedica on the use of NS1 deficient viruses as veterinarian vaccines. The García-Sastre Laboratory has received research support from Pfizer, Senhwa Biosciences, 7Hills Pharma, Pharmamar, Blade Therapeutics, Avimex, Accurius, Dynavax, Kenall Manufacturing, ImmunityBio and Nanocomposix; and A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Pagoda, Contrafect, Vaxalto, Accurius, 7Hills. The rest of the authors have no conflicts to declare.